DB:1U5

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Wave Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1U5's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

57.4%

1U5

3.5%

DE Pharmaceuticals

-0.3%

DE Market


1 Year Return

-28.2%

1U5

9.8%

DE Pharmaceuticals

5.9%

DE Market

Return vs Industry: 1U5 underperformed the German Pharmaceuticals industry which returned 9.8% over the past year.

Return vs Market: 1U5 underperformed the German Market which returned 5.7% over the past year.


Shareholder returns

1U5IndustryMarket
7 Day57.4%3.5%-0.3%
30 Day70.1%7.0%2.1%
90 Day71.0%-0.1%5.3%
1 Year-28.2%-28.2%13.3%9.8%8.4%5.9%
3 Yearn/a31.2%16.0%6.0%-2.6%
5 Yearn/a37.8%14.0%36.2%17.6%

Price Volatility Vs. Market

How volatile is Wave Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Wave Life Sciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Wave Life Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Wave Life Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Wave Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-2.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1U5 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1U5 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1U5 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1U5's revenue (4.9% per year) is forecast to grow slower than the German market (6.1% per year).

High Growth Revenue: 1U5's revenue (4.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1U5 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Wave Life Sciences performed over the past 5 years?

-40.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1U5 is currently unprofitable.

Growing Profit Margin: 1U5 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1U5 is unprofitable, and losses have increased over the past 5 years at a rate of 40.6% per year.

Accelerating Growth: Unable to compare 1U5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1U5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.2%).


Return on Equity

High ROE: 1U5 has a negative Return on Equity (-5775.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Wave Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 1U5's short term assets ($146.8M) exceed its short term liabilities ($110.5M).

Long Term Liabilities: 1U5's short term assets ($146.8M) exceed its long term liabilities ($90.1M).


Debt to Equity History and Analysis

Debt Level: 1U5 is debt free.

Reducing Debt: 1U5 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1U5 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1U5 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 44.9% each year.


Next Steps

Dividend

What is Wave Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1U5's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1U5's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1U5's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1U5's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1U5's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Paul Bolno (46 yo)

6.75yrs

Tenure

US$3,581,526

Compensation

Dr. Paul B. Bolno, M.D., MBA serves as Director at SQZ Biotechnologies Company since July 2020. He has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior t ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD3.58M) is above average for companies of similar size in the German market ($USD1.31M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Bolno
President6.75yrsUS$3.58m0.52%
$ 3.1m
Chandra Vargeese
Chief Technology Officer0.25yrUS$1.24m0.040%
$ 240.6k
Michael A. Panzara
Chief Medical Officer and Head of Therapeutics Discovery & Development1.75yrsUS$1.27m0.048%
$ 290.3k
David Gaiero
Interim Chief Financial Officer0.67yrno data0.0059%
$ 35.2k
Kyle Moran
Senior Vice President of Finance & Operations3.58yrsno datano data
Kate Rausch
Head of Investor Relations1.42yrsno datano data
Linda Rockett
General Counsel4.33yrsno datano data
Christopher Francis
Senior VP of Corporate Development & Head of Emerging Areas3.67yrsUS$1.68m0.033%
$ 199.0k
Jose Juves
Senior Vice President of Corporate Affairs & Patient Advocacy0.67yrno datano data
Kenneth Rhodes
Senior Vice President of Therapeutics Discovery0.33yrno datano data
Michael Byrne
Director of In Vivo Biology and Ophthalmologyno datano datano data
Takeshi Wada
Scientific Advisor3.67yrsUS$29.26kno data

1.8yrs

Average Tenure

49yo

Average Age

Experienced Management: 1U5's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Bolno
President6.75yrsUS$3.58m0.52%
$ 3.1m
Gregory Verdine
Director7.17yrsUS$293.16k0.082%
$ 494.1k
Mark H. Corrigan
Independent Director1yrUS$259.09kno data
Christian Henry
Independent Chairperson2.92yrsUS$206.11k0%
$ 0
Adrian Rawcliffe
Independent Director3.58yrsUS$150.88k0%
$ 0
Peter Kolchinsky
Independent Director5.67yrsUS$151.60k0%
$ 0
Ken Takanashi
Independent Director8.17yrsUS$151.33k0%
$ 0
Heidi Wagner
Independent Director1yrUS$258.28kno data
Amy Pott
Independent Director1yrUS$258.55kno data
Aik Tan
Independent Director0.083yrno datano data

3.3yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 1U5's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.


Top Shareholders

Company Information

Wave Life Sciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Wave Life Sciences Ltd.
  • Ticker: 1U5
  • Exchange: DB
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$712.311m
  • Listing Market Cap: US$600.407m
  • Shares outstanding: 36.45m
  • Website: https://www.wavelifesciences.com

Number of Employees


Location

  • Wave Life Sciences Ltd.
  • Marina One East Tower
  • No. 12-00, 7 Straits View
  • Singapore
  • 18936
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
WVENasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDNov 2015
1U5DB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2015

Biography

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The compan ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 04:22
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.